venetoclax + azacitidine + aclarubicin + cytarabine + granulocyte colony-stimulating factor

The VA-CAG regimen is a multi-drug combination therapy being investigated for the induction treatment of newly diagnosed acute myeloid leukemia (AML). It consists of venetoclax (a BCL-2 inhibitor), azacitidine (a hypomethylating agent), aclarubicin (an anthracycline-class cytotoxic antibiotic), low-dose cytarabine (a nucleoside analog antimetabolite), and granulocyte colony-stimulating factor (G-CSF). This regimen combines targeted therapy with epigenetic modulation and traditional chemotherapy, while G-CSF is used for myeloid priming to enhance the chemosensitivity of leukemic cells. Clinical studies, primarily led by the Hematology Department of the 920th Hospital, evaluate its efficacy and safety, particularly comparing different treatment durations such as 2-week versus 3-week schedules.

Other names

VA-CAG regimenVenetoclax, Azacitidine, Aclarubicin, Cytarabine, and G-CSF